These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 14977824)

  • 1. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
    Zhang Z; Wang H; Prasad G; Li M; Yu D; Bonner JA; Agrawal S; Zhang R
    Clin Cancer Res; 2004 Feb; 10(4):1263-73. PubMed ID: 14977824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
    Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
    Zhang Z; Li M; Wang H; Agrawal S; Zhang R
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11636-41. PubMed ID: 13130078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Oliver P; Zhang Z; Agrawal S; Zhang R
    Ann N Y Acad Sci; 2003 Dec; 1002():217-35. PubMed ID: 14751837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 oncogene as a target for cancer therapy: An antisense approach.
    Wang H; Zeng X; Oliver P; Le LP; Chen J; Chen L; Zhou W; Agrawal S; Zhang R
    Int J Oncol; 1999 Oct; 15(4):653-60. PubMed ID: 10493945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
    Mu Z; Hachem P; Agrawal S; Pollack A
    Prostate; 2004 Aug; 60(3):187-96. PubMed ID: 15176048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
    Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.
    Prasad G; Wang H; Agrawal S; Zhang R
    Anticancer Res; 2002; 22(1A):107-16. PubMed ID: 12017271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
    Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
    Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemosensitization by antisense oligonucleotides targeting MDM2.
    Bianco R; Ciardiello F; Tortora G
    Curr Cancer Drug Targets; 2005 Feb; 5(1):51-6. PubMed ID: 15720189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J; Yang Q; Li J; Zhou S
    Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells.
    Yang HL; Dong YB; Elliott MJ; Liu TJ; Atienza C; Stilwell A; McMasters KM
    Clin Cancer Res; 1999 Aug; 5(8):2242-50. PubMed ID: 10473112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer.
    Tortora G; Caputo R; Damiano V; Bianco R; Chen J; Agrawal S; Bianco AR; Ciardiello F
    Int J Cancer; 2000 Dec; 88(5):804-9. PubMed ID: 11072252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.
    Zhang R; Wang H; Agrawal S
    Curr Cancer Drug Targets; 2005 Feb; 5(1):43-9. PubMed ID: 15720188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53.
    Blattner C; Sparks A; Lane D
    Mol Cell Biol; 1999 May; 19(5):3704-13. PubMed ID: 10207094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.
    Nguyen KH; Hachem P; Khor LY; Salem N; Hunt KK; Calkins PR; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):238-46. PubMed ID: 15993550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel MDM2 p53-independent functions identified through RNA silencing technologies.
    Zhang Z; Wang H; Li M; Rayburn E; Agrawal S; Zhang R
    Ann N Y Acad Sci; 2005 Nov; 1058():205-14. PubMed ID: 16394138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.